PAST EXHIBITIONS

SLAS2016

January 23 – 27, 2015 • San Diego, CA
Booth #1737

Exhibitor Tutorial:
Tuesday January 26th 12.30 – 1.45pm
Room 15A

“Interrogating Ligand: Target Interactions using Back-Scattering Interferometry Yields Mechanistic Insights and Aids in Compound Prioritization”

Presented by Layton Harris Smith, PhD, Director, Drug Discovery – Florida, Sanford Burnham Prebys Medical Discovery Institute

Integral membrane proteins such as GPCRs are critical targets for drug discovery but present a host of challenges to the characterization of their binding affinities for small molecules. Determination of allosteric binding in GPCR targets is especially valuable and extremely challenging information to obtain by established binding assay platforms, but can be addressed through a label-free solution-based direct-binding technology, back-scattering interferometry (BSI).

GO TO EVENT WEBSITE >

VIB Conference – Next-Generation Antibodies and Protein Analysis: Tools and Technologies

June 15-16, 2015 • Gent, Belgium

GO TO EVENT WEBSITE >

Discovery on Target 2015

September 21-24, 2015  •   Boston, MA

Seminar: Wednesday, September 23 at 4:35pm during the track on EMERGING STRATEGIES FOR KINASE INHIBITOR DISCOVERY

Binding Studies of Type I, Type II and Type III Kinase Inhibitors against Bcr-Abl Kinase using TruBind™ Back-Scattering Interferometry presented by Scot Weinberger, Executive Vice President, Research and Development, Molecular Sensing, Inc.

Abnormal kinase activity contributes to the onset of cancer. Most kinase inhibitors are Type I inhibitors that bind to the ATP binding site or Type II that bind partially to the ATP site. TruBind(tm) technology studied the interaction of Type I, II, and III (allosteric) inhibitors of Bcr-Abl kinase. Binding studies of class I, II, and III inhibitors confirmed target engagement and provided inhibitor affinity assessment.

GO TO EVENT WEBSITE >

2nd Annual Drug Discovery USA Congress

October 29-30, 2015   •   Boston, MA

GO TO EVENT WEBSITE >

World Pre-Clinical Congress: Targeting GPCR’s

June 10-12, 2015   •   Boston, MA

Booth: #19

Seminar: “A label-free, solution-based affinity assay for allosteric GPCR ligand binding using Back-Scattering Interferometry” presented by Richard J. Isaacs, PhD, Molecular Sensing, Inc. The presentation will occur during the  Targeting GPCR’s track on Wednesday, June 10 from 3:35 – 4:05pm.

GO TO EVENT WEBSITE >

2nd NovAliX Conference – Biophysics in Drug Discovery 2015

June 9 – June 12, 2015 • Strasbourg, France

GO TO EVENT WEBSITE >

16th Annual Drug Discovery Summit 2015

June 8-9, 2015   •   Berlin, Germany

Seminar: TruBind™ BSI Analysis Facilitates Target – Small Molecule Binding Research in CNS, GPCR, Kinase, and Allosteric Studies

TruBind BSI technology uniquely provides free-solution, label-free, and conformation sensitive detection of target engagement and Kd determination for small molecule drug candidates. This presentation opens with a brief description of TruBind technology and then proceeds to review its application in the analysis of CNS aggregate – storage disease (Alzheimer’s, Lewy Body); Class A, B, and C GPCR targets; and type I, II, and III inhibitors of Bcr-Abl kinase. A particular focus upon allosteric studies will be presented.  The presentation will occur during the Target Based Discovery stream on Monday, June 8th at 11:30am-12pm.

GO TO EVENT WEBSITE >

Drug Discovery Chemistry 2015

April 21-23, 2015   •   San Diego, CA

Booth: #15

Seminar: “Binding studies of Type I, II and III kinase inhibitors against Bcr-Abl kinase using Back-Scattering Interferometry” presented by Scot R. Weinberger, EVP Molecular Sensing, Inc. The presentation will occur during the Kinase Inhibitor Chemistry track on Wednesday, April 22 from 3:10 – 3:40pm.

GO TO EVENT WEBSITE >

 SLAS2015

February 7-11, 2015   •   Washington, DC

Booth: #1619

Exhibitor Tutorial: Tuesday, February 10th from 2 – 2:45pm in room 143c.

Conformation-Sensitive Assay Detection for Accelerated Drug Discovery Research

Learn about the superior analytical power of TruBind™ Back Scattering Interferometry (BSI) technology for molecular interaction studies.
TruBind BSI technology offers significant advantages over conventional methods by providing direct binding Kd determinations and confirming target engagement by leveraging label-free, conformation-sensitive detection. Designed to analyze complex and intractable drug targets maintained in native or native-like environments, this technology platform is ideal for studying allosteric kinases and GPCR’s as membrane preps, solubilized proteins, nanodiscs or amphipols, Ion Channels, RTK’s, Allosteric Contractile Proteins, Tau and Alpha Synuclein Fibrils, Transcription Factors, and Transporter Proteins.

Molecular Sensing’s tutorial begins with a brief review of the science and technology fundamentals and then proceeds to a detailed discussion of the direct application of TruBind BSI technology to a variety of challenging targets. Come learn about TruBind Assay Services and the TruBind 100 System to see how BSI technology can accelerate your drug discovery research.

GO TO EVENT WEBSITE >

ELRIG: Drug Discovery 2014

Manchester, UK   •   September 2-3, 2014

Booth # F6

Feature: Introduction of the TruBind™ BSI System and Assay Services

Poster presentation: Novel GPR39 Agonists: Correlation of binding affinity using label-free Back Scattering Interferometry with potency in functional assays.

Industry Presentation:
The use of Backscattering Interferometry to Investigate Positive Allosteric Modulators of the M4 Receptor

3-September-2014, at 15:00

Presented by Dr. Jon Ellery, Principal Scientist, Takeda Cambridge, Ltd.

GO  TO EVENT WEBSITE >

MipTec 2014

Basel, Switzerland   •   September 23-25, 2014

Booth # A52

Features: Introduction of the TruBind™ BSI System and Assay Services

Poster presentation: Yes. Title forthcoming

Industry Symposium:
Back-Scattering Interferometry: A New Era In Label-Free, Conformation Sensitive Molecular Interaction Assay Technology for Drug discovery

25th September, 12:30 – 13:30

Presented by Scot Weinberger, Co-founder of MSI, EVP of R&D

The MSI MipTech Industry Symposium will present the enabling analytical power of Back-Scattering Interferometry (BSI) as applied to molecular interaction studies in drug discovery research. BSI provides direct binding Kd determinations with label-free, conformation-sensitive detection.  BSI delivers significant advantages over conventional methods for complex and intractable drug targets maintained in native or native-like environments, including: allosteric kinases and GPCR’s as membrane preps, solubilized proteins, nanodiscs or amphipols; Ion Channels; RTK’s; Allosteric Contractile Proteins;  Tau and Alpha Synuclein Fibrils; Transcription Factors; and Transporter Proteins.

The Symposium begins with a review of BSI theory and fundamentals and then proceeds to discuss the direct application of BSI technology to a variety of challenging targets including:  GPCR’s, contractile proteins, kinases, and fibrils.  Molecular Sensing will introduce its TruBind™ Assay Services and TruBind 100 automated BSI system.  An interactive question and answer format will be utilized throughout the course of the symposium.

GO TO EVENT WEBSITE >